site stats

Platinum and taxane

Webb13 apr. 2024 · Combination therapy with the novel agent BXCL701 and pembrolizumab showed strong clinical activity in in patients with platinum-resistant small cell neuroendocrine carcinoma metastatic castration-resistant ... and 50% had prior taxane chemotherapy. The median duration of follow-up was 30.8 weeks (range, 1.9-86.9), and … WebbEpithelial ovarian cancer (EOC) is the leading cause of gynecological cancer-related death. The high mortality and morbidity associated with EOC are mostly due to late diagnosis and chemotherapy drug resistance. Currently, the standard first-line chemotherapy regimen is systemic administration of platinum-based chemotherapy combined with a taxane. A …

Ring Enhancement in Non-Neoplastic Breast Tissue on MRI During ...

Webb9 feb. 2012 · platinum-resistant disease taxane-pretreated disease age: 20–75 years old PS (performance status): 0–2 one of the followings, or both of them: patients have measurable lesion patients have assessable lesion with elevated CA-125 (more than 70 U/ml) no prior treatment with irinotecan, topotecan or etoposide no prior radiation to … Webb21 sep. 2016 · The cellular toxicity of taxanes and platinum agents are likely controlled by the actions of multiple genes. 8 - 10 Genes involved in transport (eg, ABCB1, ABCC1, and ABCC2 ), metabolism (cytochrome P450s), and pharmacodynamics (eg, TP53, CDKN1A) all appear to play a role in taxane efficacy. 9 Similarly, platinum agents such as carboplatin … nursing home chico ca https://ashishbommina.com

Dr. Ashish Vora, PhD - Manager in the KnowledgeBase - Linkedin

Webb14 apr. 2024 · Purpose Sarcopenia is prevalent in ovarian cancer and contributes to poor survival. This study is aimed at investigating the association of prognostic nutritional index (PNI) with muscle loss and survival outcomes in patients with ovarian cancer. Methods This retrospective study analyzed 650 patients with ovarian cancer treated with primary … Webbmanaging platinum and taxane agent HSRs, continued im-provements can be made to refine existing risk stratification strategies for patients with platinum and taxane HSRs. TABLE I. Four-step reintroduction protocols reported for carboplatin1,7-9 Step Pradelli et al1 Takase et al7 Altwerger et al8 Li et al9 1 1:1000 1:1000 1:1000 1:1 Webb2 juli 2024 · This study evaluates the safety and efficacy of the combination of Avelumab, (a fully human anti-programmed death ligand 1 (PD-L1) IgG1 antibody) in combination with a taxane chemotherapy (docetaxel) in patients with metastatic urothelial cancer who are either ineligible to receive cisplatin based chemotherapy, refractory to cisplatin in first … nj community health center

National Center for Biotechnology Information

Category:Platinum and Taxane Based Adjuvant and Neoadjuvant ... - PubMed

Tags:Platinum and taxane

Platinum and taxane

Pharmacogenetic Assessment of Toxicity and Outcome After Platinum …

Webb14 apr. 2024 · Clinical trial data of patients with stage Ic to IV ovarian cancer treated with platinum and taxane combination chemotherapy suggest that 2-year overall survival is only around 66% . For those with stage III and IV disease, the median time to radiologic progression after initial surgery and chemotherapy is as short as 12–18 months and the … WebbIntroduction. Ovarian cancer is a leading cause of death in gynecologic malignancies. 1 The high mortality is mainly caused by advanced stage at presentation in most patients. Even after the combination of cytoreductive surgery and systemic platinum and taxane treatment, most patients relapse and eventually succumb to the disease. 2 Therefore, …

Platinum and taxane

Did you know?

WebbWe have traditionally used 2 drug combination (5-FU plus taxane based or platinum based), but there is no study comparing this 2 regimens. The objective of the current analysis … Webb10 nov. 2024 · cancers Review Mechanisms of Taxane Resistance Sara M. Maloney 1,2, Camden A. Hoover 3, Lorena V. Morejon-Lasso 3 and Jenifer R. Prosperi 1,2,3,* 1 Harper Cancer Research Institute, South Bend, IN 46617, USA; [email protected] 2 Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, South Bend, …

Webb6 apr. 2024 · Dr. Sharma reviewed several of the key studies of platinum agents in the neoadjuvant setting, starting with the large BrighTNess trial. 2 The three-arm study with an anthracycline, cyclophosphamide, and a taxane (AC → T) backbone evaluated the addition of carboplatin as well as the addition of carboplatin plus low-dose veliparib. . Carboplatin … WebbSeveral strategies such as premedication, skin testing, and desensitization protocols are available to potentially allow for administration of platinum- or taxane-based …

WebbRT @LugawMd: Anti-cancer drugs: "-mab" indicates a monoclonal antibody "-tinib" indicates a tyrosine kinase inhibitor "-ciclib" indicates a cyclin-dependent kinase inhibitor "-taxel" indicates a taxane mitotic inhibitor "-platin" indicates a platinum-containing alkylating agent. 10 Apr 2024 19:20:45 WebbWith a median follow-up of 23 months, the median overall survival was 43 months for survivors. The 3- and 5-year survival rates were 53% and 30%, respectively. Conclusion: …

WebbDespite frequent initial responses to platinum/taxane therapy, most patients with high-grade serous ovarian cancer (HGSOC) eventually develop resistance that leads to low responsiveness to any drug and shortened survival. To design effective strategies that improve prognosis, there is a critical need to identify and target the mechanisms that lead

Webb3 mars 2015 · The guideline article “Management of hypersensitivity to platinum- and taxane-based chemotherapy: cepo review and clinical recommendations” in this journal for the management of hypersensitivity reactions ( HSR) to this group of chemotherapy agents is useful in clinical practice [...] Share and Cite MDPI and ACS Style Bahl, M.; Dean, T. nursing home christmas doorWebbThe purpose of this study was to investigate the association of sarcopenia with chemotherapy toxicity in patients with EOC. Methods: EOC patients diagnosed between 6/2000 and 2/2024 who received platinum and taxane-based chemotherapy were included. Age, race, stage, grade, BMI, comorbidities, treatment, and outcomes were collected. nursing home christmas decorationsWebb15 juni 2009 · Although platinum and taxane‐based chemotherapy is the standard management of primary ovarian cancer, there are limited studies available that investigate the role of an in vitrodrug resistance assay in the prediction of response to the primary platinum and taxane combination chemotherapy and survival for ovarian … nj community eventsWebb• “A Randomized Controlled Trial of Neo-adjuvant Platinum-Taxane Chemotherapy Versus Taxane Chemotherapy and Metformin Versus not, In Women with Triple Negative Large Operable and Locally Advanced Breast Cancer” Techniques – Quantitative PCR, DNA isolation from snap frozen fresh tissue. Diagnostic work: nj computer showsWebbPlatin HSRs typically occur after multiple cycles of chemotherapy, reflecting the development of drug IgE sensitization, while taxane HSRs often occur on first or … nursing home christmas lunchWebb6 dec. 2024 · Platinum (Pt) derivatives such as cisplatin and carboplatin are the class of drugs with proven activity against triple-negative breast cancer (TNBC). This is due to … nj community fcu moorestown njWebb5 mars 2024 · Data from patients with squamous-cell lung cancer in KEYNOTE-407 support the use of the platinum–taxane–anti-PD-1 combination, and there is clinical evidence of … nj commission on the blind